Biofrontera Locks Phase 1 PK Data for Ameluz® Label Expansion

Event summary

  • Biofrontera completed its Phase 1 pharmacokinetics study for Ameluz® on February 11, 2026, evaluating treatment of actinic keratoses (AKs) on trunk and extremities.
  • The study assessed systemic exposure to ALA and PpIX during PDT with Ameluz® and BF-RhodoLED® XL lamp in 17 patients.
  • Positive Phase 3 efficacy results previously announced will complement the PK data for a supplemental NDA submission expected in Q3 2026.
  • The expanded label aims to treat AK fields up to 240 cm², extending beyond the current 60 cm² indication for face and scalp.

The big picture

Biofrontera's Phase 1 PK data lock is a critical step toward expanding Ameluz®'s label to treat larger AK fields on the trunk and extremities. This move aligns with broader industry trends toward broader indications for dermatological treatments, potentially increasing market access and revenue. The strategic shift from face and scalp to larger body areas could significantly enhance Ameluz®'s competitive edge in the actinic keratosis treatment market.

What we're watching

Regulatory Approval
Whether the FDA will approve the expanded label for Ameluz® in Q3 2026, enabling treatment of larger AK fields.
Market Positioning
How the expanded indication will strengthen Ameluz®'s clinical positioning and long-term growth potential.
Commercialization Strategy
The pace at which Biofrontera can commercialize the expanded indication if approved.